US down, UK up as FTSE 100 strikes new all-time high

Published 15-MAY-2017 12:29 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

After trading in a fairly tight range for most of the week between approximately 20,800 points and 21,000 points, the Dow finished at the midpoint of that range at 20,896 points. Meanwhile, the FTSE 100 claimed a new all-time high, closing up 0.7% at 7435 points, equating to a week on week increase of 2%.

This came on the back of commentary from the Bank of England which indicated there was no risk of near-term rate rises.

In a week where there was limited market moving news flow, Friday wasn’t an ideal finish with President Trump’s firing of former FBI director James Corney creating negative sentiment, and from a macro perspective retail sales disappointed, as did the CPI numbers which came in below expectations.

The NASDAQ only made a minor gain of five points to close at 6121 points.

It was a different story in Europe with both the UK and major European mainland indices gaining significant ground.

In terms of stock specific moves, the star performer was AstraZeneca plc as it gained more than 9% after the company announced positive trial results for stage III lung cancer patients being treated with its Imfinzi drug.

The initial trial results mean the drug is the first Immuno-Oncology (IO) medicine to show superior progression free survival in a trial setting.

The DAX rallied on the back of positive macro data which featured robust GDP growth. The 0.5% increase in the index saw it close at 12,770 points, just shy of the record all-time high of 12,783 points struck earlier in the week.

The Paris CAC 40 recovered most of its loss ground after dipping on Thursday, closing at 5405 points, representing a gain of 0.4%.

On the commodities front, oil was relatively flat, closing just shy of the US$48 per barrel mark. However, it finished the session on a strong note rallying circa 1% in the afternoon session.

Gold continues to hover in the vicinity of US$1225 per ounce, and gained 0.3% to finish just above that level.

There was a solid rally in the iron ore price as it increased approximately 1.7% to US$61.38 per tonne.

Base metals were mixed with nickel flat, copper up slightly, and lead and zinc falling 2.4% and 1.5% respectively.

The fall in the zinc price takes it back to a three-week low of US$1.15 per pound. The situation with lead is similar as it sits marginally above its three-week low.

The Australian dollar strengthened on Friday, briefly pushing above the US$0.74 level before closing at US$0.738.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free